Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
about
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 casesAdvantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center studyPrimary CNS lymphoma: a clinician's guide.Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervous system lymphoma.Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma.Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.The Diagnosis and Treatment of Primary CNS Lymphoma
P2860
Q24202784-26E4A566-5AA9-4314-90C3-3A5E4E41E231Q24236726-B582E7CC-3F58-41C7-9DE2-16A19042E674Q35802782-811DCD9C-5194-427D-8ACA-39FACB1CDF21Q35869493-E5C9AC1D-0337-4EEE-A21C-A41C7FE411CBQ36674028-88D33587-2A98-4B9B-A39F-392EB4A97DD2Q38053442-B989ADFB-74A8-4DEA-A4DD-5B46083694F8Q38436030-7B45207A-9D5C-4CB9-99D8-D07A1543AD1CQ39471971-A89FFBC7-9FBD-401A-96DB-81FE4618FEA8Q41769568-B70D21BC-439B-4C8F-9F2F-CB746FC736FDQ42453536-ECCB1C28-AE5A-477E-8DC3-07BB298F4757Q47790904-000B178E-EBBE-48C5-84B0-420AB9F50E4CQ56967801-209B1AF2-F95C-494E-BA81-7B5857C19AFC
P2860
Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Monotherapy with methotrexate ...... : a single institution cohort.
@ast
Monotherapy with methotrexate ...... : a single institution cohort.
@en
type
label
Monotherapy with methotrexate ...... : a single institution cohort.
@ast
Monotherapy with methotrexate ...... : a single institution cohort.
@en
prefLabel
Monotherapy with methotrexate ...... : a single institution cohort.
@ast
Monotherapy with methotrexate ...... : a single institution cohort.
@en
P2093
P2860
P1476
Monotherapy with methotrexate ...... : a single institution cohort.
@en
P2093
Ephraim Hochberg
Fred Hochberg
Julien Cobert
Nina Woldenberg
P2860
P2888
P304
P356
10.1007/S11060-009-0090-3
P577
2009-12-18T00:00:00Z
P5875
P6179
1000665286